2022
Effectiveness and Safety of Biologic Therapy in Hispanic Vs Non-Hispanic Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study
Nguyen N, Luo J, Paul P, Kim J, Syal G, Ha C, Rudrapatna V, Park S, Parekh N, Zheng K, Sauk J, Limketkai B, Fleshner P, Eisenstein S, Ramamoorthy S, Melmed G, Dulai P, Boland B, Mahadevan U, Sandborn W, Ohno-Machado L, McGovern D, Singh S. Effectiveness and Safety of Biologic Therapy in Hispanic Vs Non-Hispanic Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study. Clinical Gastroenterology And Hepatology 2022, 21: 173-181.e5. PMID: 35644340, PMCID: PMC9701245, DOI: 10.1016/j.cgh.2022.05.008.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseNon-Hispanic patientsBiologic-treated patientsHispanic patientsSerious infectionsBiologic therapyBowel diseasePropensity score-matched cohortBurden of inflammationRisk of hospitalizationHigh ratePropensity-score matchingCause hospitalizationAdult patientsBiologic initiationCohort studyBiologic agentsMedication useHigh burdenHigh riskHospitalizationPatientsSurvival analysisSurgeryAbstractText
2021
No Benefit of Continuing 5-Aminosalicylates in Patients with Crohn’s Disease Treated with Anti-metabolite Therapy
Picetti D, Kim J, Zhu W, Sandborn W, Jairath V, Singh S. No Benefit of Continuing 5-Aminosalicylates in Patients with Crohn’s Disease Treated with Anti-metabolite Therapy. Digestive Diseases And Sciences 2021, 67: 3115-3123. PMID: 34797442, PMCID: PMC9117569, DOI: 10.1007/s10620-021-07301-x.Peer-Reviewed Original ResearchConceptsAnti-metabolite therapyCrohn's diseaseCox proportional hazards analysisCD-related hospitalizationCD-related surgeryAdministrative claims databaseProportional hazards analysisCorticosteroid useTreatment escalationClaims databaseClinical benefitResidual confoundingHigh riskPatientsDisease severityMonotherapyDiseaseKey covariatesTherapyHazard analysisOutcomesRiskEscalationMethodsPatientsHospitalization